 |
 |
|
|
RESÚMENES DICIEMBRE 2005 |
Psychotic Disorders & Antipsychotics
(Haga un click en la información del journal para acceder al resúmen)
Atypical
antipsychotic drugs and organization of long-term semantic memory:
multidimensional scaling and cluster analyses of category fluency performance
in schizophrenia
Sumiyoshi C, Sumiyoshi T,
Roy A, Jayathilake K, Meltzer HY
Int J Neuropsychopharmacol. 2005 Nov 29;:1-7
The effect of extract of ginkgo biloba addition to olanzapine on
therapeutic effect and antioxidant enzyme levels in patients with schizophrenia
MURAD ATMACA, ERTAN TEZCAN, MURAT KULOGLU, BILAL
USTUNDAG, AND OZLEM KIRTAS
Psychiatry and Clinical Neurosciences. Volume
59 Issue 6 Page 652 - December 2005
Cytochrome P450 3A
inhibitor itraconazole affects plasma concentrations of risperidone and
9-hydroxyrisperidone in schizophrenic patients
Sun Min Jung,
Kyoung-Ah Kim, Hyun-Kee Cho, Il Geun Jung, Pil-Whan Park, Won Tan Byun and
Ji-Young Park
Clinical
Pharmacology & Therapeutics. Volume 78, Issue 5, November 2005, Pages
520-528
Effects
of age and sex on olanzapine plasma concentrations
Weiss U, Marksteiner J,
Kemmler G, Saria A, Aichhorn W
J Clin Psychopharmacol. 2005 Dec;25(6):570-4
Dose-dependent
interaction of paroxetine with risperidone in schizophrenic patients
Saito M, Yasui-Furukori N,
Nakagami T, Furukori H, Kaneko S
J Clin Psychopharmacol. 2005 Dec;25(6):527-32
A
6-Month Prospective Observational Study on the Effects of Quetiapine on Sexual
Functioning
Montejo Gonzalez AL,
Rico-Villademoros F, Tafalla M, Majadas S; Spanish Working Group for the Study
of Psychotropic-Related Sexual Dysfunction
J Clin Psychopharmacol. 2005 Dec;25(6):533-538
Cognitive
functioning in patients with schizophrenia and bipolar disorder: A quantitative
review
Lydia Krabbendam,
Baer Arts, Jim van Os and André Aleman
Schizophrenia
Research. Volume 80, Issues 2-3, 15 December 2005, Pages 137-149
Franck Schürhoff,
Audrey Laguerre, Andreï Szöke, Alexandre Méary and Marion Leboyer
Schizophrenia
Research. Volume 80, Issues 2-3, 15 December 2005, Pages 235-242
Jeffrey S. Bedwell
and Reesa S. Donnelly
Schizophrenia
Research. Volume 80, Issues 2-3, 15 December 2005, Pages 263-269
Cheryl Corcoran,
Agnes Whitaker, Eliza Coleman, Jane Fried, Judith Feldman, Nora Goudsmit and
Dolores Malaspina
Schizophrenia
Research. Volume 80, Issues 2-3, 15 December 2005, Pages 283-293
Vadim Geller, Igor
Gorzaltsan, Tatiana Shleifer, R.H. Belmaker and Yuly Bersudsky
Schizophrenia
Research. Volume 80, Issues 2-3, 15 December 2005, Pages 343-347
A
meta-analysis of profile and time-course of symptom change in acute
schizophrenia treated with atypical antipsychotics
Sherwood M, Thornton AE,
Honer WG
Int J Neuropsychopharmacol. 2005 Sep 5;:1-10
Michael Breakspear
Australian and New Zealand Journal of Psychiatry.
Volume 40 Issue 1 Page 20 - January 2006
Homayoun Amini, Javad Alaghband-rad, Abbas Omid,
Vandad Sharifi, Rozita Davari-Ashtiani, Farzad Momeni and Zahra Aminipour
Australasian Psychiatry. Volume 13 Issue
4 Page 388 - December 2005
Klaus Mann,
Wolfgang Rossbach, Matthias J. Müller, Florian Müller-Siecheneder, Tobias Pott,
Iris Linde, Ralf W. Dittmann and Christoph Hiemke
Psychoneuroendocrinology. Volume 31, Issue 2, February 2006, Pages
256-264
Symptomatology and social inference: A theory of mind study of
schizophrenia and psychotic affective disorder
Dominic Marjoram ,
Clare Gardner , Jonathan Burns , Patrick Miller , Stephen M. Lawrie , Eve C.
Johnstone
Cognitive Neuropsychiatry. Volume 10, Number 5 /
November 2005: 347 - 359
Correlation
Between Plasma Homovanillic Acid Levels and the Response to Atypical
Antipsychotics in Male Patients With Schizophrenia
Kaneda Y, Kawamura I,
Ohmori T
Clin Neuropharmacol. 2005
November/December;28(6):262-264
Venous
Thromboembolism Among Elderly Patients Treated With Atypical and Conventional
Antipsychotic Agents
Liperoti R, Pedone C,
Lapane KL, Mor V, Bernabei R, Gambassi G
Arch Intern Med. 2005 Dec 12;165(22):2677-2682
Correlations Between rCBF and Symptoms in Two Independent
Cohorts of Drug-Free Patients with Schizophrenia
Adrienne C Lahti, Martin A Weiler,
Henry H Holcomb, Carol A Tamminga, William T Carpenter Jr and Robert McMahon
Neuropsychopharmacology (2006) 31, 221-230
Electroencephalogram slowing, sleepiness and treatment response in patients with schizophrenia during olanzapine treatment
Adam Wichniak, Tomasz Szafra
Journal of
Psychopharmacology, Vol. 20, No. 1, 80-85 (2006)
Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia
Hideki Hosojima, Takashi Togo, Toshinari Odawara, Koichi Hasegawa,
Satoshi Miura, Yuiko Kato, Akiko Kanai, Akihiko Kase, Hirotake Uchikado, Yoshio
Hirayasu
Journal of
Psychopharmacology, Vol. 20, No. 1, 75-79 (2006)
Niina Ezewuzie, David Taylor
Journal
of Psychopharmacology, Vol. 20, No. 1, 86-90 (2006)
Does negative
symptom change relate to neurocognitive change in schizophrenia? Implications
for targeted treatments
Morris D. Bell and
Aaron L. Mishara
Schizophrenia
Research. Volume 81, Issue 1, 1 January 2006, Pages 17-27
Leisa A. Glantz,
John H. Gilmore, Jeffrey A. Lieberman and L. Fredrik Jarskog
Schizophrenia
Research. Volume 81, Issue 1, 1 January 2006, Pages 47-63
One-year
double-blind study of the neurocognitive efficacy of olanzapine, risperidone,
and haloperidol in schizophrenia
Richard S.E. Keefe,
Carrie A. Young, Stephanie L. Rock, Scot E. Purdon, James M. Gold, Alan Breier
and HGGN Study Group
Schizophrenia
Research. Volume 81, Issue 1, 1 January 2006, Pages 1-15
Tardive
dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence
and management strategies in patients with schizophrenia.
Margolese HC, Chouinard G,
Kolivakis TT, Beauclair L, Miller R, Annable L
Can J Psychiatry. 2005
Oct;50(11):703-14
James M Stone and Lyn S Pilowsky
Expert Review of Neurotherapeutics. January 2006, Vol. 6, No. 1,
Pages 57-64
Discontinuation
of treatment of schizophrenic patients is driven by poor symptom response: a
pooled post-hoc analysis of four atypical antipsychotic drugs
Hong
Liu-Seifert, David H Adams and Bruce J Kinon
BMC Medicine 2005, 3:21; 23 December
Leptin and
cholesterol levels are low in major depressive disorder, but high in
schizophrenia
Guey-Mei Jow,
Tsung-Tsair Yang and Chun-Lan Chen
Journal
of Affective Disorders. Volume 90, Issue 1, January 2006, Pages 21-27